Haisco Pharmaceutical Group dividend and valuation
Valuation
Haisco Pharmaceutical Group paid ¥0.79 per share in dividends over the last 12 months (yield 1.5%). Last ex-dividend date: September 4, 2026. The P/E ratio is 44.1. The average price target of 2 analysts is ¥88.47.
Data as of November 21, 2026
Haisco Pharmaceutical Group compared with similar companies
Haisco Pharmaceutical Group's P/E (trailing 12 months): 44.1, +6% against the median of a group of 8 similar companies (41.7).
| Metric | Haisco Pharmaceutical Group | Median | 25th–75th percentile | Band |
|---|---|---|---|---|
| P/E (trailing 12 months) | 44.1 | 41.7 | 33.9 – 93.5 | Middle |
| Forward P/E | 38.0 | 31.7 | 20.4 – 43.6 | Middle |
| EV/EBITDA | 37.9 | 37.9 | 18.2 – 67.6 | Middle |
| Price/book | 9.99 | 5.24 | 2.69 – 8.16 | High |
| Price/sales | 9.88 | 8.89 | 4.67 – 31.6 | Middle |
| Gross margin | 77.3% | 74.6% | 49.8% – 79.1% | Middle |
| Operating margin | 21.1% | 14.9% | 6.8% – 30.3% | Middle |
| Net margin | 21.5% | 7.8% | 5.4% – 21.4% | High |
| ROE | 25.6% | 10.4% | 5.0% – 19.8% | High |
| Debt/equity | 0.38 | 0.11 | 0.05 – 0.40 | Middle |
Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.
TickerLandia analysisHow it is calculated
Companies in the group: same industry, similar size
Haisco Pharmaceutical Group: valuation over time
On the latest fiscal year's earnings (2025), Haisco Pharmaceutical Group's P/E today is 228.2, above the median of its last 10 fiscal years (57.7; between 29.7 and 223.1 from 2016 to 2025). Relative to earnings, the stock costs more than it used to. The dividend yield (1.5%) is above the median of the last 9 fiscal years (1.2%).
| Fiscal year | Price at year end | Earnings per share | P/E | Dividend per share | Yield |
|---|---|---|---|---|---|
| 2025 | ¥51.32 | ¥0.23 | 223.1 | ¥0.27 | 0.5% |
| 2024 | ¥33.25 | ¥0.35 | 95.0 | ¥0.42 | 1.2% |
| 2023 | ¥23.15 | ¥0.27 | 85.7 | ¥0.20 | 0.9% |
| 2022 | ¥22.25 | ¥0.26 | 85.6 | — | — |
| 2021 | ¥20.40 | ¥0.32 | 63.7 | ¥0.19 | 0.9% |
| 2020 | ¥17.52 | ¥0.59 | 29.7 | ¥0.37 | 2.1% |
| 2019 | ¥20.36 | ¥0.46 | 44.3 | ¥0.09 | 0.5% |
| 2018 | ¥11.89 | ¥0.31 | 38.4 | ¥0.19 | 1.6% |
| 2017 | ¥11.37 | ¥0.22 | 51.7 | ¥0.28 | 2.5% |
| 2016 | ¥15.63 | ¥0.41 | 38.1 | ¥0.46 | 2.9% |
TickerLandia calculation: closing price on the last trading day of the fiscal year divided by diluted earnings per share from the annual report (positive earnings only); yield = dividend per share for the year divided by the same price. Prices adjusted for splits. Today's P/E is today's price divided by the latest fiscal year's earnings per share, so it compares with the years above; today's yield uses dividends over the last 12 months.
TickerLandia analysisHow it is calculated
Other metrics
Valuation multiples
- Market cap
- ¥59.87B
- Enterprise value
- ¥59.02B
- EV/revenue
- 9.74
Profitability and growth
- ROA
- 9.8%
- ROIC
- 10.8%
- Revenue growth (year over year)
- 44.3%
- Earnings growth (year over year)
- 203.2%
Financial health
- Total cash
- ¥2.75B
- Total debt
- ¥2.27B
- Current ratio
- 1.94
- Quick ratio
- 1.75
- Altman Z-Score
- 14.2
- Piotroski F-Score
- 8.00
Dividends
- Annual dividend per share
- ¥0.79
- Dividend yield
- 1.5%
- Payout ratio
- 66.6%
- Ex-dividend date
- September 4, 2026
Analysts and estimates
- Average price target
- ¥88.47
- Median price target
- ¥88.47
- High price target
- ¥96.63
- Low price target
- ¥80.30
- Analysts with a price target
- 2
- Forward EPS
- ¥1.38
- EPS estimate, current year
- ¥1.55
Shares and trading
- Beta
- -0.08
- Average volume
- 4.55M
- Shares outstanding
- 1.14B
- Float
- 266.87M
- Institutional ownership
- 11.6%
- Insider ownership
- 74.5%
